Slow approvals put India’s clinical trials at risk
Drugs firms complain that sluggish bureaucracy in New Delhi and a lack of legal clarity on how to conduct clinical trials have created a climate of regulatory uncertainty in the market. The post Slow...
View ArticleGovt panel proposes to regulate prices of patented drugs
A panel formed under the ministry of chemicals and fertilizers has recommended setting up a committee to negotiate with drugmakers to fix prices of costly drugs used to treat deadly diseases such as...
View ArticleNovartis patent blow: Why Big Pharma can’t quit India
Much of the new business will still come from cheap generics made by local companies, but Western firms are also seeking to put their brands on unpatented medicines, prompting the likes of Abbott...
View ArticleUS trade office reviewing SC ruling against Novartis
The United States is considering its response to the Supreme Court ruling against Novartis, which US drug manufacturers warn is the latest sign of a "deteriorating" environment for intellectual...
View ArticleOverweight Indian pharma stocks defy Asian market rout. Here’s why
So far this year, Lupin Ltd has climbed 32 percent, Dr. Reddy's 31 percent, Glenmark Pharmaceuticals 42 percent and Wockhardt 29 percent The post Overweight Indian pharma stocks defy Asian market rout....
View Article
